Accuray Continues Global Expansion in South Asia and Announces the First Two CyberKnife® VSI™ Systems in India
Accuray Incorporated (MM) (NASDAQ:ARAY)
Historical Stock Chart
3 Years : From Mar 2012 to Mar 2015
SUNNYVALE, California, Nov. 21, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Medanta - The Medicity Cancer Institute, and the Roentgen-BLK Super Speciality Hospital both recently acquired and started treating patients with the CyberKnife® VSI™ System the premier solution for full-body radiosurgery marking the first-in-country CyberKnife VSI Systems in India.
Cancer incidence is growing in India with 900,000 new cancer cases and 400,000 cancer deaths annually. Cancers account for eight percent of total deaths in India thus creating a larger demand for cancer treatments.
By enriching their therapeutic offerings in radiation oncology, Medanta - The Medicity Cancer Institute and the Roentgen-BLK Radiation Oncology Center can now provide patients treatment with the CyberKnife System and expand the patient population that can now benefit from CyberKnife radiosurgery and stereotactic body radiation therapy (SBRT) in the region.
"The CyberKnife System is increasingly being used as an alternative to conventional radiation therapy in situations where its targeting accuracy allows a shorter and more intense course of radiation, including radiosurgery for brain tumors. We are pleased to have introduced this innovative technology at Medanta and look forward to witnessing the benefits that the System offers, including real-time tracking with automatic correction of tumors that move throughout the body. The CyberKnife System comes as a significant development in cancer therapy for patients as well as doctors as it offer the most precise treatment option for a wide range of patients," said Naresh Trehan, M.D., Chairman and Managing Director of Medanta - The Medicity.
"We are always refining radiation oncology treatment methods to deliver the highest-quality patient care possible, while working to also reduce or eliminate the side effects that accompany radiation treatment. Using the CyberKnife System allows our radiation oncologists to provide the most up-to-date technology available to accurately target tumors, deliver treatments with pinpoint accuracy and ensure that tumors get the most effective ablative dose while healthy tissues and critical structures are spared," said Praneet Kumar, M.D., CEO of Roentgen-BLK Radiation Oncology Center.
Building upon the foundation of accuracy and precision in radiosurgery, the CyberKnife System extends these benefits to fractionated high precision radiation therapy with robotic intensity-modulated radiotherapy (IMRT) that can be delivered anywhere in the body, including intracranial, head and neck, spine, lung, liver and prostate. The enhanced spectrum of treatment options allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated area, or patients requiring partial breast irradiation. With more than 700 hundred peer-reviewed publications and a rapidly increasing number of treated patients, the growing community of CyberKnife users is discovering more applications that can be helped by the technological edge that the CyberKnife System provides.
About Medanta - The Medicity
Medanta – The Medicity is one of India's largest multi-super specialty institutes located in Gurgaon, a bustling town in the National Capital Region. Founded by eminent cardiac surgeon, Dr. Naresh Trehan, the institution has been envisioned with the aim of bringing to India the highest standards of medical care along with clinical research, education and training. It brings together an outstanding pool of doctors, scientists and clinical researchers to foster collaborative, multidisciplinary investigation, inspiring new ideas and discoveries; and translating scientific advances more swiftly into new ways of diagnosing and treating patients and preventing diseases. Medanta through its research integrates modern and traditional forms of medicine to provide accessible and affordable healthcare. For more information visit www.medanta.org.
About Roentgen-BLK's Cancer Center
The BLK Super Speciality Hospital's Cancer Center ("BLKCC") is one of the most modern and comprehensive cancer centers in Northern India. With over 100 beds dedicated for oncology services, the department is equipped with ultra-modern equipment and infrastructure. BLK Super-Speciality hospital is both NABH and NABL accredited, certifying the quality of standard of care and the processes that have been put in place for healthcare delivery. For more information, please visit http://www.blkhospital.com.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife® and TomoTherapy® Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, 667 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to growth of cancer patients, clinical applications, clinical results and patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as modified in its Form 10-Q filed on November 8, 2012, and as updated from time to time in its other SEC filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.